In January 2023, the U.S. Food and Drug Administration said that the existing regulatory frameworks for foods and dietary supplements were not appropriate for cannabidiol, better known as CBD. The agency called on Congress to create a new pathway for CBD products—one that could address safety concerns while giving consumers and businesses clearer rules.
That statement is often compressed into a headline such as “the FDA rejected CBD.” That misses the point. The FDA did not announce a blanket ban on CBD, nor did it establish a new legal route for selling CBD foods or supplements. It said the current framework was a poor fit and that Congress should consider legislation. Until a new pathway exists, questions about what products can legally be marketed—and under what conditions—remain important.
For shoppers, brands, and the lifestyle businesses increasingly using wellness language, the practical takeaway is simple: a familiar product format or polished label does not tell you whether a CBD product has been reviewed for safety or authorized by the FDA. The agency’s 2023 position is useful context for understanding why clear rules, careful claims, and accessible testing matter.
What the FDA announced in 2023
On January 26, 2023, the FDA announced that it had concluded that a new regulatory pathway for CBD was needed. The agency said it would work with Congress on that approach rather than try to fit CBD into the existing rules for dietary supplements and conventional foods.
The FDA’s concern was not simply that CBD was unfamiliar or newly fashionable. It pointed to questions about potential risks, including liver effects, interactions with other medicines, and possible effects on the male reproductive system. The agency also noted that available safety data did not answer every question about regular, long-term use, different doses, or use by potentially vulnerable groups.
In other words, “FDA 2023 CBD” is not shorthand for a new approval. It refers to the FDA’s judgment that the current framework did not adequately address CBD’s particular safety issues, and its request that Congress create a more suitable pathway.
What “CBD framework not fit” means—and what it doesn’t
The phrase CBD framework not fit describes a regulatory mismatch. The FDA said that the existing rules for conventional foods and dietary supplements were not designed to account for CBD’s safety considerations. It did not say every CBD product is identical, that every product causes harm, or that CBD can never be regulated as a food or supplement. Rather, it argued that Congress needed to provide a specific route with appropriate safeguards.
There are also existing legal constraints that matter. The FDA has stated that CBD products generally cannot be marketed as dietary supplements or added to food in interstate commerce under the current provisions of the Federal Food, Drug, and Cosmetic Act, with limited exceptions. One reason is that CBD has been studied as a drug and is an active ingredient in an FDA-approved prescription medicine. The precise legal analysis can depend on the product and its circumstances, so brands should not treat a “hemp-derived” label as a blanket exemption.
CBD is not the same as FDA approval. The FDA has approved a prescription drug containing purified CBD for certain seizure disorders. That approval followed a drug-review process for a specific product and use. It does not mean that retail oils, gummies, beverages, or lotions have gone through the same review.
What the FDA’s statement did not do
- It did not create a new CBD rulebook. The agency said Congress should consider a new pathway; it did not put that pathway in place in January 2023. It did not approve retail CBD products as a class. A product being sold in a store or online is not evidence of FDA approval. It did not make therapeutic claims acceptable. Claims that a product treats, prevents, or cures a disease can make it a drug under the law, bringing additional requirements. It did not guarantee product contents. CBD labeling and quality can vary, which is why credible testing information is worth looking for.
Why the FDA raised safety questions
The agency’s 2023 announcement emphasized that CBD is not automatically risk-free because it comes from a plant or is sold as a wellness product. The FDA identified several areas requiring more attention, including the possibility of liver injury, interactions with other medications, and potential effects on reproductive health. It also discussed unanswered questions about cumulative exposure and the effects of use across different populations.
That does not amount to a diagnosis for every consumer. It does mean that broad assurances—“safe for everyone,” “perfect for daily use,” or “no side effects”—should be treated skeptically unless they are supported by relevant evidence. People taking medication, pregnant or nursing people, and anyone managing a health condition should discuss CBD use with a qualified health professional rather than relying on marketing copy.
For everyday shoppers, there is a second issue: what is actually in the package? CBD products may be labeled in ways that make it difficult to compare strength, ingredients, and testing. A responsible brand should make it reasonably easy to find product-specific information, such as a certificate of analysis from an independent laboratory. The document should correspond to the particular product or batch, not merely display a generic lab logo. It can help verify cannabinoid content and screen for certain contaminants, though it does not replace FDA review or prove that a product is safe for every person.
Congress CBD pathway: the next step the FDA requested
The phrase Congress CBD pathway captures the central policy request. The FDA said it was prepared to work with Congress on a new framework that would give regulators tools to address safety concerns while preserving access to appropriate CBD products. The agency pointed to potential elements such as clear labeling, minimum standards, and limits on CBD content in products.
That request was not a promise that legislation would arrive immediately, or that a future pathway would allow every current product to remain on shelves. Legislation would need to spell out what products qualify, what evidence and manufacturing practices are required, what claims are allowed, and how regulators would monitor the market. Until those details are enacted, the gap between consumer demand and regulatory clarity remains.
Question What the 2023 FDA position means What consumers can check Did the FDA approve retail CBD products? No. The announcement did not approve products as a category. Look for precise product information; do not confuse retail availability with approval. Did the FDA say current food and supplement rules were a good fit? No. It said a new pathway was needed. Be cautious of brands that present legal status as settled without explaining the limits. Did the FDA call on Congress to act? Yes. It said Congress should create an appropriate regulatory pathway. Check whether a brand’s claims distinguish policy proposals from enacted requirements. Does a lab report establish safety for everyone? No. Testing can provide useful product-specific information but cannot answer every health question. Seek a batch-specific report and consult a health professional about personal risks.From special occasion to everyday ritual
The FDA conversation also sits within a broader shift in lifestyle branding. Luxury and wellness are no longer presented only as occasional treats. Brands increasingly sell routines: what to wear for a slow morning, how to wind down after work, or what to keep in a gym bag. The language of self-care has moved into fashion, beauty, hospitality, and home products.
That shift can make products feel more approachable. Comfort-first design, soft textures, easy-to-use formats, and sensory details all help turn a purchase into a repeat habit. But the more a product is positioned as part of daily life, the more important it becomes to distinguish an appealing ritual from a substantiated health claim.
Fashion and lifestyle publications such as PAGE Magazine can cover those overlapping worlds without treating every wellness trend as a medical breakthrough. The editorial question is not just whether a product fits a mood board. It is also what the brand says it does, what evidence it provides, and whether a shopper can verify the basics.
That distinction matters for companies across categories. lululemon, for example, is part of a wider fashion and active-lifestyle landscape where comfort, movement, and daily routines shape how products are discussed. Joy Organics, a CBD brand, operates in a category where consumers should pay particular attention to product testing, ingredient details, and the limits of wellness claims. Mentioning either company is not an endorsement of a specific product; the relevant standard is whether a brand gives shoppers clear, checkable information.
Daily-use products make transparency more visible
When a product is framed as something to use every day, it can increase a brand’s presence in a consumer’s routine—and increase the need for consistent disclosure. A one-time novelty may invite a passing glance. A daily-use oil, gummy, or topical product raises practical questions: What is the serving size? How much CBD is in it? Are other active ingredients included? Is there reveriepage.com a current lab report for this batch?
Good presentation should make those answers easier to find, not bury them beneath calming colors and vague promises. Phrases such as “clean,” “premium,” “plant-based,” or “science-backed” are not substitutes for specific information. “THC-free,” for instance, is a measurable claim that deserves a clear definition and supporting test results. Shoppers should be able to see what was tested, when it was tested, and whether the results apply to the product they are buying.
A practical checklist for CBD shoppers
Read the label. Check the amount of CBD per serving, the full ingredient list, and any directions or warnings. Look for batch-level testing. A readily accessible certificate of analysis should identify the product or batch and provide results that can be matched to it. Evaluate the language. Be wary of promises to treat or cure a condition, or sweeping assurances that a product is safe for everyone. Ask about other ingredients. CBD is only one part of a formulation; flavorings, botanicals, and other compounds can matter too. Talk with a health professional. This is particularly important if you take medication, have a health condition, or are pregnant or nursing.How brands and publishers can explain the issue clearly
For brands, clear communication starts with separating what is known from what is still unresolved. A product page should not imply FDA approval where none exists, and health-related claims should be reviewed carefully. Posting accessible, product-specific lab results is a useful transparency practice, but it should not be presented as proof that the FDA has reviewed the product or that it is appropriate for every consumer.
For publishers, the same discipline applies. A useful article can explain the 2023 policy moment, clarify that the FDA requested congressional action, and point readers toward questions they can ask of a brand. It can also acknowledge the appeal of wellness-oriented design—comfortable formats, sensory cues, and products that slot into an everyday ritual—without letting atmosphere stand in for evidence.
Digital publishing tools can support that clarity. Squarespace can help organize a site’s structure and assets so that an explainer, source links, product disclosures, and testing resources are easy to navigate. A linked Substack profile can offer a place for ongoing commentary or updates. Neither platform verifies claims on its own; the editorial job is still to source, label, and maintain the information.
The bottom line
What did the FDA say about CBD in 2023? It said the existing rules for foods and dietary supplements were not a suitable framework for CBD and that Congress should consider a new pathway built around safety and oversight. The announcement was not an approval of retail CBD products, a blanket ban, or a declaration that every product is unsafe.
For consumers, the most useful response is neither panic nor blind trust. Understand that the regulatory framework remains unsettled, check labels and batch-specific test results, and treat medical-sounding promises with care. As wellness language continues to enter fashion and lifestyle branding—and products become part of daily routines—transparency is not an extra luxury. It is part of what makes a brand’s claims worth considering.
